Search

Displaying results 3681 - 3690 of 8412 in total
  1. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  2. Drug

    ASI402

    go.drugbank.com/drugs/DB06373
    Investigational

    ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.

  3. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it across the blood-brain barrier. In...

  4. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient.

  5. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    Increased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa

  6. Drug

    Tozasertib

    go.drugbank.com/drugs/DB19675
    Investigational

    Tozasertib has a monoisotopic molecular weight of 464.21 Da. … Tozasertib is under investigation in clinical trial NCT02532868 (A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)).

  7. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells. Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF, which is a critical plasma glycop...

    Synonyms: (618-THREONINE,709-ASPARTIC ACID)VON WILLEBRAND FACTOR HOMO SAPIENS (1381A>T,1472H>D VARIANT) BLOOD COAGULATION FACTOR
  8. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  9. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic. … Pipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed.

  10. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates